Literature DB >> 23572405

Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism.

Kemal Ağbaht1, Murat Faik Erdogan, Rifat Emral, Nilgun Baskal, Sevim Güllü.   

Abstract

Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis. We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism. Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). The same measurements were repeated an average 3 months later, when all patients achieved euthyroidism. Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin. Fasting serum glucose tended to be higher during thyrotoxicosis. The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r = 0.801, p < 0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r = -0.844, p < 0.001). Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism. The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism. The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572405     DOI: 10.1007/s12020-013-9951-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

Review 1.  Central nervous system control of food intake.

Authors:  M W Schwartz; S C Woods; D Porte; R J Seeley; D G Baskin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

2.  Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism.

Authors:  Hans Wahrenberg; Anders Wennlund; Johan Hoffstedt
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

3.  The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity.

Authors:  Roberto Coppari; Masumi Ichinose; Charlotte E Lee; Abigail E Pullen; Christopher D Kenny; Robert A McGovern; Vinsee Tang; Shun M Liu; Thomas Ludwig; Streamson C Chua; Bradford B Lowell; Joel K Elmquist
Journal:  Cell Metab       Date:  2005-01       Impact factor: 27.287

4.  Effect of hyperthyroidism on clearance and secretion of glucagon in man.

Authors:  G Dimitriadis; E Hatziagelaki; P Mitrou; V Lambadiari; E Maratou; A E Raptis; J E Gerich; S A Raptis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2011-01-24       Impact factor: 2.949

5.  Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells.

Authors:  Jen-Chieh Chuang; Ichiro Sakata; Daisuke Kohno; Mario Perello; Sherri Osborne-Lawrence; Joyce J Repa; Jeffrey M Zigman
Journal:  Mol Endocrinol       Date:  2011-06-30

6.  Thyroid status and leptin in Basedow-Graves and multinodular goiter patients.

Authors:  R Seven
Journal:  J Toxicol Environ Health A       Date:  2001-08-24

7.  Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents.

Authors:  Ayako Ikezaki; Hiroshi Hosoda; Keiko Ito; Saika Iwama; Naoko Miura; Hisafumi Matsuoka; Chisato Kondo; Masayasu Kojima; Kenji Kangawa; Shigetaka Sugihara
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

Review 8.  Insulin action in hyperthyroidism: a focus on muscle and adipose tissue.

Authors:  Panayota Mitrou; Sotirios A Raptis; George Dimitriadis
Journal:  Endocr Rev       Date:  2010-06-02       Impact factor: 19.871

9.  Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes.

Authors:  Seppo M Pöykkö; Eija Kellokoski; Sohvi Hörkkö; Heikki Kauma; Y Antero Kesäniemi; Olavi Ukkola
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

10.  Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development.

Authors:  Yan Li; Jie Hai; Lake Li; Xuehui Chen; Hua Peng; Meng Cao; Qinggui Zhang
Journal:  Endocrine       Date:  2012-07-29       Impact factor: 3.633

View more
  6 in total

1.  Thyroid Nodules in Type 2 Diabetes Mellitus.

Authors:  Hong-Mei Zhang; Qi-Wen Feng; Yi-Xin Niu; Qing Su; Xia Wang
Journal:  Curr Med Sci       Date:  2019-07-25

Review 2.  Selenium and Selenoproteins at the Intersection of Type 2 Diabetes and Thyroid Pathophysiology.

Authors:  Francesca Gorini; Cristina Vassalle
Journal:  Antioxidants (Basel)       Date:  2022-06-16

3.  Association of decreased muscle mass with reduced bone mineral density in patients with Graves' disease.

Authors:  Yongze Zhang; Yuzhen Ke; Lingning Huang; Ximei Shen; Sunjie Yan; Fengying Zhao; Yimei Li; Yuxi Lin
Journal:  Endocrine       Date:  2022-01-22       Impact factor: 3.633

4.  Clinical sensitivity and specificity of serum total bilirubin - A study on thyroid status in clinically euthyroid non-obese, overweight, and obese type 2 diabetics.

Authors:  Rajendran Jayanthi; Abu Raghavan Srinivasan; Anandraj Lokesh Maran
Journal:  Int J Health Sci (Qassim)       Date:  2019 Jul-Aug

5.  A longitudinal study of thyroid markers during pregnancy and the risk of gestational diabetes mellitus and post-partum glucose metabolism.

Authors:  Lei Tang; Ping Li; Hua Zhou; Ling Li
Journal:  Diabetes Metab Res Rev       Date:  2021-02-22       Impact factor: 4.876

6.  High T3 Induces β-Cell Insulin Resistance via Endoplasmic Reticulum Stress.

Authors:  Bo Liang; Liyun Liu; Huibin Huang; Liangyi Li; Jingxiong Zhou
Journal:  Mediators Inflamm       Date:  2020-07-22       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.